4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00862680

Enrollment

Registered

2009-03-17

Start date

2009-03-12

Completion date

2019-04-28

Last updated

2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

Brief summary

This trial studies how well 4 dimensional (D) positron emission tomography/computed tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung. Diagnostic procedures, such as PET/CT, may help find and diagnose disease and find out how far the disease has spread. But the motions made by breathing can reduce the image quality of the scan. Adjusting the scanner to 4D may allow for more breathing motion may improve the quality of the PET/CT images.

Detailed description

PRIMARY OBJECTIVES: I. Study the impact of 4D positron emission tomography/computed tomography (PET/CT) imaging on the evaluation and staging of lung and colorectal cancer. OUTLINE: Participants undergo 4D PET/CT scan over up to 12 minutes.

Interventions

PROCEDURE4-Dimensional Computed Tomography

Undergo 4D PET/CT

PROCEDURE4D PET Scan

Undergo 4D PET/CT scan

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. * Patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.

Exclusion criteria

* Patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.

Design outcomes

Primary

Measure	Time frame	Description
Maximum lesion standardized uptake value (SUVmax) for gated and ungated positron emission tomography/computed tomography (PET/CT) scans	Up to 10 years	Will be compared using a one-sided paired t-test.
Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients	Up to 10 years	two nuclear medicine physicians will assess the impact of the difference in SUVmax on the lesion detectablility and staging of the evaluated patients.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026